semaglutide and crohn's disease Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, therapeutic potential GLP-1 Use in Crohn's Disease:

The GLP-1 consumer over-indexes on food and beverage at about 9% higher than the non-user. Circana data shows 5.3% of consumers are actively embracing GLP-1s, and the number may rise to double-digits for those who have at least tried the drug, according to Lyons Wyatt

[10] [11] Based on data from retatrutide clinical trials (NEJM, 2023) and experience with similar approved agents, patients may experience: Redness, swelling, or itching at the injection site, which typically resolves within a few hours to days Bruising or mild pain immediately following injection Nodules or localised reactions beneath the skin, which may occur with repeated injections at the same site These reactions are generally mild and self-limiting

While both options can lead to significant weight loss, one relies on ongoing medication support and the other involves permanent surgical changes to the digestive system

Semaglutide is delivered through a tiny injection that is virtually pain free